13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001892770
Total reported value
$189.2M
$189.2M
89 檔
96.1%
At the close of Q4 2024, Knott David M Jr disclosed equity holdings valued at approximately $189.2M, spread across 89 reported holdings.
During Q4 2024, Knott David M Jr's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CLMT, APO, JAAA) accounted for 96.1% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CLMT | Calumet Inc | Stock-Other | 29.08% | — | -15.58% | |
| 2 | APO | Apollo Global Management Inc | Stock-Financials | 13.44% | -0.85% | — | |
| 3 | JAAA | Janus Henderson Aaa Clo ETF | ETF-Other | 10.83% | -0.30% | +595.98% | |
| 4 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 7.73% | +1.46% | — | |
| 5 | DCGO | Docgo Inc | Stock-Other | 4.71% | -0.27% | — | |
| 6 | ✓ | Janus Henderson AAA CLO ETF | ETF-Other | 2.90% | — | — | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.68% | — | -11.50% | |
| 8 | PFE | Pfizer Inc | Stock-Healthcare | 2.44% | -0.13% | +13.36% | |
| 9 | ICLO | Invesco Aaa Clo F/r Note ETF | ETF-Other | 1.87% | — | +6.67% | |
| 10 | JPM | Jpmorgan Chase & Co | Stock-Financials | 1.82% | -0.28% | — | |
| 11 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.58% | -1.77% | EXIT | |
| 12 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.44% | +1.93% | -11.71% | |
| 13 | OABI | Omniab Inc | Stock-Other | 1.40% | — | -4.70% | |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.32% | — | — | |
| 15 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 1.23% | +0.78% | — | |
| 16 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.20% | — | +15.18% | |
| 17 | ARDX | Ardelyx Inc | Stock-Other | 1.12% | -0.03% | -10.34% | |
| 18 | ESGRP | Enstar Group Limited - Deposita | Stock-Other | 0.87% | — | — | |
| 19 | IMVT | Immunovant Inc | Stock-Other | 0.82% | — | — | |
| 20 | CSX | Csx CORP | Stock-Industrials | 0.82% | — | — | |
| 21 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.73% | +0.13% | — | |
| 22 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.70% | — | +23.11% | |
| 23 | AB | Alliancebernstein Holding LP | Stock-Other | 0.64% | -0.18% | — | |
| 24 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.61% | -0.82% | +4.79% | |
| 25 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.57% | — | — | |
| 26 | CLOZ | Eldridge Bbb-b Clo ETF | ETF-Other | 0.47% | -0.06% | -91.19% | |
| 27 | RHP | Ryman Hospitality Properties | Stock-Real Estate | 0.45% | +0.03% | — | |
| 28 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.42% | -0.06% | EXIT | |
| 29 | ATYR | Atyr Pharma Inc | Stock-Other | 0.40% | — | +187.51% | |
| 30 | COLL | Collegium Pharmaceutical Inc | Stock-Other | 0.34% | — | — | |
| 31 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.33% | +0.11% | — | |
| 32 | ABBV | Abbvie Inc | Stock-Healthcare | 0.32% | — | — | |
| 33 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.30% | — | — | |
| 34 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.29% | — | — | |
| 35 | KMB | Kimberly-clark CORP | Stock-Consumer Staples | 0.28% | — | — | |
| 36 | 6D8 | Dupont De Nemours Inc | Stock-Other | 0.27% | -0.10% | EXIT | |
| 37 | MSFT | Microsoft CORP | Stock-Tech | 0.24% | -0.03% | — | |
| 38 | CTVA | Corteva Inc | Stock-Materials | 0.24% | -0.01% | — | |
| 39 | MDT | Medtronic plc | Stock-Healthcare | 0.23% | — | — | |
| 40 | ✓ | Stock-Other | 0.23% | — | — | ||
| 41 | AAPL | Apple Inc | Stock-Tech | 0.23% | — | — | |
| 42 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.21% | — | +1921.69% | |
| 43 | MDLZ | Mondelez International Inc-a | Stock-Consumer Staples | 0.19% | -0.01% | — | |
| 44 | HELP | Cybin Inc | Stock-Other | 0.19% | +0.29% | — | |
| 45 | CNQ | Canadian Natural Resources | Stock-Energy | 0.19% | -0.14% | — | |
| 46 | XOMA | Xoma Royalty Corporation | Stock-Other | 0.19% | — | — | |
| 47 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.17% | -0.35% | — | |
| 48 | IBM | Intl Business Machines CORP | Stock-Tech | 0.17% | +0.01% | — | |
| 49 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.14% | — | -82.94% | |
| 50 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.08% | — | — |
According to official SEC Form 13F filings, Knott David M Jr reported a total U.S. public equity portfolio value of $189.2M across 89 disclosed positions in Q4 2024.
During Q4 2024, Knott David M Jr's top holdings by market value included CLMT (29.1%)、APO (13.4%)、JAAA (10.8%). The largest single position, CLMT, represented 29.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q4 2024, Knott David M Jr made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.